The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions

[1]  Fernanda Polubriaginof,et al.  The feasibility of using natural language processing to extract clinical information from breast pathology reports , 2012, Journal of pathology informatics.

[2]  Karen A Gelmon,et al.  Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.

[3]  Jack Cuzick,et al.  Preventive therapy for breast cancer: a consensus statement. , 2011, The Lancet. Oncology.

[4]  Q. Ding,et al.  The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis , 2011, Journal of Cancer Research and Clinical Oncology.

[5]  V Shane Pankratz,et al.  Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Philbrick,et al.  Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Joseph P. Costantino,et al.  Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer , 2010, Cancer Prevention Research.

[8]  Sarah M. Greene,et al.  Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid , 2010, Breast Cancer Research and Treatment.

[9]  R. Vierkant,et al.  Assessment of the accuracy of the Gail model in women with atypical hyperplasia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Vierkant,et al.  Stratification of breast cancer risk in women with atypia: a Mayo cohort study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Colditz,et al.  Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia , 2007, Cancer.

[12]  W. Dupont,et al.  Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial breast biopsy , 2006, Cancer.

[13]  C. Bartoli,et al.  Interpretation of the risk associated with the unexpected finding of lobular carcinoma in situ , 2006, Annals of Surgical Oncology.

[14]  R. Severson,et al.  Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  V Shane Pankratz,et al.  Benign breast disease and the risk of breast cancer. , 2005, The New England journal of medicine.

[16]  L. Holmberg,et al.  Risk of subsequent invasive breast cancer after breast carcinoma in situ , 2000, The Lancet.

[17]  S. Cummings,et al.  The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial , 2000 .

[18]  B. Fisher.  Tamoxifen for prevention of breast cancer. , 1999, The Medical letter on drugs and therapeutics.

[19]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[20]  C. la Vecchia,et al.  Second cancers following in situ carcinoma of the breast , 1998, International journal of cancer.

[21]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[22]  G. Colditz,et al.  Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  N. Weiss,et al.  Risk of contralateral breast cancer among women with carcinoma in situ of the breast. , 1997, Annals of surgery.

[24]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[25]  C A Bodian,et al.  Lobular neoplasia: Long term risk of breast cancer and relation to other factors , 1996, Cancer.

[26]  W. Dupont,et al.  Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. , 1991, Human pathology.

[27]  David L. Page,et al.  Diagnostic Histopathology of the Breast , 1988 .

[28]  E. Frykberg.  Lobular Carcinoma In Situ of the Breast , 1999, The breast journal.

[29]  W. Dupont,et al.  Atypical hyperplastic lesions of the female breast: A long-term follow-up study , 1986 .

[30]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[31]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[32]  C. Kosloff,et al.  Lobular carcinoma in situ of the breast Detailed analysis of 99 patients with average follow‐up of 24 years , 1978, The American journal of surgical pathology.

[33]  C. Bodian,et al.  Lobular neoplasia (so‐called lobular carcinoma in situ) of the breast , 1978, Cancer.